Skip to main content

Table 2 Association of sST2 with all-cause mortality, cardiovascular mortality and MACE in cox proportional hazards models

From: Association of soluble ST2 with all-cause and cardiovascular mortality in renal transplant recipients: a single-centre cohort study

  

Model 1

Model 2

 

Unadjusted HR

(95% CI)

P value

Adjusted HR (95% CI)

P value

Adjusted HR (95% CI)

P value

All-cause mortality (n = 171)

 sST2 (per twofold increase)

1.31 (1.05–1.63)

0.016

1.36 (1.05–1.76)

0.018

1.33 (1.06–1.67)a

0.014

 sST2 ≥ 35 ng/ml

1.41 (1.04–1.90)

0.025

1.45 (1.03–2.04)

0.035

1.36 (1.00–1.85)a

0.049

 sST2 ≥ 33 ng/ml (optimal)

1.52 (1.12–2.05)

0.007

1.62 (1.15–2.29)

0.006

1.46 (1.07–1.99)a

0.016

Cardiovascular mortality (n = 62)

 sST2 (per twofold increase)

1.50 (1.05–2.13)

0.024

1.65 (1.09–2.48)

0.017

1.50 (1.03–2.18)a

0.033

 sST2 ≥ 35 ng/ml

1.31 (0.80–2.16)

0.288

1.43 (0.80–2.56)

0.233

1.16 (0.69–1.94)a

0.576

 sST2 ≥ 41 ng/ml (optimal)

1.72 (1.04–2.85)

0.035

1.90 (1.06–3.43)

0.032

1.57 (0.93–2.67)a

0.092

MACE (n = 131)

 sST2 (per twofold increase)

1.36 (1.07–1.74)

0.013

1.30 (0.97–1.73)

0.079

1.40 (1.08–1.80)b

0.010

 sST2 ≥ 35 ng/ml

1.34 (0.95–1.88)

0.096

1.09 (0.74–1.63)

0.659

1.19 (0.84–1.71)b

0.332

 sST2 ≥ 24 ng/ml (optimal)

1.75 (1.09–2.82)

0.021

1.70 (0.97–3.01)

0.066

1.89 (1.14–3.13)b

0.013

  1. Abbreviations: BMI body mass index, CI confidence interval, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, HR hazard ratio, hs-CRP high-sensitivity C-reactive protein, IHD ischemic heart disease, MACE major adverse cardiovascular events, RRT renal replacement therapy, sST2 soluble ST2
  2. Model 1: adjusted for age, sex, diabetes, history of hypertension, cholesterol/HDL ratio, BMI, smoking status, history of CVD, eGFR, proteinuria category, hs-CRP
  3. aModel 2 – mortality: adjusted for age, diabetes, total RRT time (= pre-transplant dialysis time + time-post transplant), serum creatinine, smoking status, history of IHD
  4. bModel 2 – MACE: adjusted for age, diabetes, LDL-cholesterol, number of transplant grafts, serum creatinine, smoking status, history of IHD